Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Alpha Tau Medical Ltd ( (DRTS) ) has issued an announcement.
Alpha Tau Medical Ltd. reported on May 11, 2026, interim data from its U.S. REGAIN trial of Alpha DaRT in recurrent glioblastoma, a highly lethal and treatment-resistant brain cancer. The first three patients, treated between December 2025 and March 2026 at The Ohio State University Comprehensive Cancer Center, showed 100% local disease control, with two complete responses and one case of stable disease accompanied by a 30% tumor reduction.
As of the May 3, 2026 cutoff, no local or distant recurrences or lasting procedure-related symptoms were observed, and a single grade 3 serious adverse event resolved with steroids, supporting a favorable early safety profile. Investigators and management characterized the responses as unusually strong versus historical benchmarks for recurrent GBM, underscoring Alpha Tau’s strategic push to position Alpha DaRT as a novel option in central nervous system oncology as the REGAIN study progresses toward enrolling up to ten U.S. patients.
The most recent analyst rating on (DRTS) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
Spark’s Take on DRTS Stock
According to Spark, TipRanks’ AI Analyst, DRTS is a Neutral.
The score is held back primarily by very weak financial performance (no revenue, widening losses, and accelerating cash burn), which increases funding and dilution risk. Technicals are more constructive on a longer-term basis (above 50/100/200-day averages with neutral momentum), but valuation is limited by negative earnings and no dividend support.
To see Spark’s full report on DRTS stock, click here.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company focused on developing and potentially commercializing Alpha DaRT, an alpha-radiation therapy for solid tumors. The technology, conceived at Tel Aviv University, delivers radium-224-based sources directly into tumors to generate highly localized, high-energy alpha emissions intended to destroy cancer cells while sparing surrounding healthy tissue.
Average Trading Volume: 332,975
Technical Sentiment Signal: Buy
Current Market Cap: $749M
Learn more about DRTS stock on TipRanks’ Stock Analysis page.